At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 579 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Placebo for Obesity and Overweight. Completed, enrolled 579 participants across 65 sites in 4 countries.
Detailed Summary
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overweight
CountriesArgentina, Brazil, Puerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartMar 2021
Primary CompletionApr 2023
Study CompletionMay 2023
TodayJul 2026
First PostedDec 7, 2020
Enrollment StartMar 29, 2021
Primary CompletionApr 20, 2023
Study CompletionMay 12, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.6 years ago
Interventions
Tirzepatidedrug
Administered SC
Placeboother
Administered SC